Sugi Predict

Sugi Predict / Compounds / SCHEMBL3422201

SCHEMBL3422201

SCHEMBL3422201

COC(=O)CCCNC(=O)OC(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.61
▸ MEN1 O00255 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ MAOA P21397 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ CA2 P00918 9/20 0.50
▸ CA1 P00915 8/20 0.50
▸ CA12 O43570 5/20 0.50
▸ CA9 Q16790 4/20 0.50
▸ TSHR P16473 3/20 0.50
▸ EPHX2 P34913 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ EPHX1 P07099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15373104 0.95 TDP1 (0.64) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2582992 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL22276612 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL22276594 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL17485438 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL25092096 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL19078966 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL16081806 0.93 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL27437838 0.91 TDP1 (0.62) TDP1MEN1GAAKMT2AMAOA
SCHEMBL23477276 0.89 TDP1 (0.61) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4249470-A1 METHOD FOR PREPARING ALPHA-AMINO ACIDS PHILIPPS-UNIVERSITÄT MARBURG (DE) 2023-09-27 — — EP disclosed
US-11708348-B2 Protease inhibitors for treatment of coronavirus infections THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-25 — — US disclosed
CN-115776891-A STAT degradants and uses thereof 凯麦拉医疗公司 2023-03-10 — — CN disclosed
US-20230024012-A1 Protease Inhibitors for Treatment of Coronavirus Infections THE SCRIPPS RESEARCH INSTITUTE 2023-01-26 — — US disclosed
US-20210323914-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3842437-A1 HIGH ACTIVITY STING PROTEIN AGONIST Adlai Nortye Biopharma Co., Ltd. (CN) 2021-06-30 — — EP disclosed
WO-2020038387-A1 HIGH ACTIVITY STING PROTEIN AGONIST 杭州阿诺生物医药科技有限公司 2020-02-27 — — WO disclosed
CN-106164072-B Monocyclic lactam organic compounds for the treatment of bacterial infections 诺华股份有限公司 2019-10-01 — — CN disclosed
US-20190210992-A1 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS TEXAS HEART INSTITUTE (US) 2019-07-11 — — US disclosed
US-20190142964-A1 DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF Ashvattha Therapeutics, Inc. 2019-05-16 — — US disclosed
WO-2012068251-A2 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS TEXAS HEART INSTITUTE (US) 2012-05-24 — — WO disclosed
US-20120003155-A1 DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES NATIONAL INSTITUTES OF HEALTH (US) 2012-01-05 — — US disclosed
US-7988854-B2 Dialysate regeneration system for portable human dialysis CHEMICA TECHNOLOGIES, INC. (US) 2011-08-02 — — US disclosed
WO-2011062965-A2 TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2011-05-26 — — WO disclosed
WO-2010065709-A2 HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF KHAN AMIN (US) 2010-06-10 — — WO disclosed
US-20100022549-A1 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE THE SCRIPPS RESEARCH INSTITUTE (US) 2010-01-28 — — US disclosed
US-20100022549-A1 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE THE SCRIPPS RESEARCH INSTITUTE (US) 2010-01-28 — — US disclosed
WO-2010011864-A2 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE THE SCRIPPS RESEARCH INSTITUTE (US) 2010-01-28 — — WO disclosed
US-20090020471-A1 DIALYSATE REGENERATION SYSTEM FOR PORTABLE DIALYSIS CHEMICA TECHNOLOGIES, LLC (US) 2009-01-22 — — US disclosed
US-7435342-B2 Dialysate regeneration system for portable human dialysis CHEMICA TECHNOLOGIES, INC. (US) 2008-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024012-A1 Protease Inhibitors for Treatment of Coronavirus Infections ACE, ACE2, TMPRSS2 TDP1 3714/4885MEN1 3185/4885GAA 694/4885
US-20120003155-A1 DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES PAM, MUC1, AADAC TDP1 4821/4885MEN1 2320/4885GAA 2693/4885
US-20190142964-A1 DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF TLR3, CD40LG, OXGR1 TDP1 3025/4885MEN1 3686/4885GAA 2402/4885
US-20190210992-A1 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS ITGB7, ITGAL, ITGB1 TDP1 4768/4885MEN1 3828/4885GAA 3294/4885
US-11708348-B2 Protease inhibitors for treatment of coronavirus infections ACE, ACE2, TMPRSS2 TDP1 3714/4885MEN1 3185/4885GAA 694/4885
US-20100022549-A1 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE H1-4, H1-5, H1-3 TDP1 3951/4885MEN1 1696/4885GAA 4032/4885
US-20210323914-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY RNASEH1, RNASE1, HNRNPA1 TDP1 3408/4885MEN1 2694/4885GAA 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.